Equities

SpectraCure AB (publ)

SpectraCure AB (publ)

Actions
  • Price (SEK)1.65
  • Today's Change0.064 / 4.05%
  • Shares traded81.92k
  • 1 Year change-60.81%
  • Beta0.6044
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.

  • Revenue in SEK (TTM)2.36m
  • Net income in SEK-21.18m
  • Incorporated2003
  • Employees13.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Episurf Medical AB12.80m-79.70m98.17m26.00--0.9679--7.67-0.2072-0.20720.03010.15580.1059--5.57457,142.80-66.09-47.46-75.45-52.01-----624.22-1,019.296.17--0.0296--53.6219.78-22.64---0.4158--
Immunovia AB (publ)885.00k-116.12m98.43m10.00--2.68--111.22-1.30-1.300.00990.21620.0071--14.3980,454.55-93.50-41.33-133.56-44.24-6,702.03-7,553.76-13,120.79-20,879.29--2.480.3064--37.5536.48-84.09---50.93--
Observe Medical ASA-99.90bn-99.90bn101.16m5.00--0.646----------0.5635-----------32.60---49.80--32.83---256.250.193--0.3425--43.14204.81-18.82--32.69--
Redsense Medical AB (publ)23.77m-3.98m103.93m5.00--3.24--4.37-0.2871-0.28711.651.950.75247.584.184,754,400.00-12.58-18.66-14.51-20.9920.47-2.72-16.72-46.284.00-89.340.00--74.1128.9448.47---23.62--
Iconovo AB2.92m-40.21m106.55m28.00--0.7154--36.54-2.74-2.740.1967.020.0215--1.14100,561.70-29.61-25.43-33.16-28.24635.97134.57-1,378.66-215.16---1,179.070.0668---58.65-9.884.71--34.70--
Luxbright AB4.20m-22.23m110.43m10.00--3.71--26.28-0.24-0.240.04540.26410.104--4.14420,270.00-55.02-61.39-62.23-70.36-134.43-577.85-528.90-2,529.110.7743-4,539.470.0084--55.58---20.07------
Vo2 Cap Holding AB (publ)348.03m-55.15m112.06m94.00--0.6226--0.322-0.9759-0.97596.463.160.7992--8.213,378,952.00-12.66-0.2564-17.29-0.383935.7823.36-15.84-0.2409---6.950.1429---26.0985.65-57.92---17.96--
BibbInstruments AB0.00-12.21m116.81m4.00--3.63-----0.4477-0.44770.001.100.00-------34.78-39.57-36.66-42.71--59.36---8,032.404.41--0.00------2.72---1.94--
Q linea AB2.27m-218.33m128.88m97.00--5.02--56.88-1.87-1.870.01940.2190.01070.12243.0117,842.52-103.05-59.66-149.74-66.14-124.10-378.58-9,635.17-4,046.970.4141--0.7825---65.2833.0214.64--41.94--
Glycorex Transplantation AB (publ)31.03m-27.83m129.17m15.00--3.53--4.16-0.3768-0.37680.42010.51860.4120.83823.691,348,913.00-36.96-11.30-46.32-13.1782.9191.60-89.70-33.241.09-71.860.2084---17.04-2.15-254.06---0.5593--
Arcoma AB171.33m12.98m144.38m32.0011.122.457.050.84270.98440.984412.994.481.873.487.875,526,807.0014.181.1224.212.0138.2937.667.580.75681.2425.820.000.0030.366.4134.81--22.75--
SpectraCure AB (publ)2.36m-21.18m153.66m13.00--1.30--65.00-0.218-0.2180.02431.210.0166--24.63157,600.00-14.82-12.75-15.91-13.62442.39195.30-895.85-494.40----0.0494---3.30--19.46------
Toleranzia AB0.00-7.12m153.91m11.00--0.7548-----0.0361-0.03610.000.75260.00----0.00-4.31-7.45-4.56-7.78------------0.0481------11.79--63.90--
Bactiquant A/S13.96m-22.50m154.76m----14.59--11.09-0.6558-0.65580.40640.29060.51012.945.06---82.23-41.26-92.65-47.16-24.3412.89-161.20-71.772.73-9.480.5326---0.689--7.62------
Nanexa AB26.66m-64.42m178.44m16.00--2.16--6.69-0.6156-0.61560.20870.60840.2333-25.663.491,403,211.00-56.37-40.77-74.68-48.77113.0477.27-241.64-532.261.90--0.0149--925.42147.00-30.44--39.10--
Neola Medical AB0.00-9.39m190.81m7.00--2.67-----0.141-0.1410.001.020.00----0.00-12.96-17.04-13.98-18.46--4,237.20---5,258.78----0.00------12.97--55.46--
Data as of Nov 22 2024. Currency figures normalised to SpectraCure AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
FCG Fonder ABas of 31 Oct 202423.41k0.02%
Data from 31 Oct 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.